167 results about "Lower affinity" patented technology

A method for identifying nucleic acid ligands to target molecules using the SELEX procedure wherein the candidate nucleic acids contain photoreactive groups and nucleic acid ligands identified thereby are claimed. The complexes of increased affinity nucleic acids and target molecules formed in the procedure are crosslinked by irradiation to facilitate separation from unbound nucleic acids. In other methods partitioning of high and low affinity nucleic acids is facilitated by primer extension steps as shown in the figure in which chain termination nucleotides, digestion resistant nucleotides or nucleotides that allow retention of the cDNA product on an affinity matrix are differentially incorporated into the cDNA products of either the high or low affinity nucleic acids and the cDNA products are treated accordingly to amplification, enzymatic or chemical digestion or by contact with an affinity matrix.

A level of affinity between a first user and many other users is considered when prioritizing content display when browsing, and ratings display when searching for programs in an electronic program guide or in a browser interface of a playback software application. Ratings from users who have high affinity with the first user are shown with priority over ratings from users who have low affinity with the first user. And, when browsing, programs rated highly by users having high affinity with the first user are shown with priority over programs rated poorly by the users having high affinity with the first user, and programs rated highly by users having low affinity with the first user.

In certain embodiments this invention pertains to methods of detecting and/or quantifying rare mutant nucleic acids in populations of nucleic acids in which the wild-type nucleic acids are in substantially greater abundance than the rare mutants. In various embodiments the methods utilize short high affinity oligonucleotides targeted to the wild type rather than the minority or mutant sequence. Rather than directly detecting mutant DNA, these probes block detection of wild type DNA. These “blocker” probes can be used in combination with longer “detection” probes or PCR primers to amplify and/or identify the minority mutation in, e.g., clinical specimens. The combination of short high affinity blocker probes and longer, lower affinity detection probes eliminates the single base specificity/complexity tradeoff in the design of nucleic acid probes.

A semiconductor light source is disclosed comprising a substrate, lower and upper claddings, a waveguide region with imbedded active area, and electrical contacts to provide voltage necessary for the wavelength tuning. The active region includes single or several heterojunction periods sandwiched between charge accumulation layers. Each of the active region periods comprises higher and lower affinity semiconductor layers with type-II band alignment. The charge carrier accumulation in the charge accumulation layers results in electric field build-up and leads to the formation of generally triangular electron and hole potential wells in the higher and lower affinity layers. Nonequillibrium carriers can be created in the active region by means of electrical injection or optical pumping. Radiative recombination occurs between the electrons and holes, accumulated in the ground states of the triangular potential wells formed in the high- and low-affinity layers of each active region periods. The ground state energy in the triangular wells and the radiation wavelength can be tuned by changing the voltage drop across the active region.

A compound of general formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl, R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond, methyl, ethyl, wherein R19, R20 and R21 are H or —CH₂X, NT is selected from H, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group, CT is selected from hydrogen, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and may be used to treat a wide range of inflammatory conditions. Also disclosed is a DNA molecule and a corresponding vector encoding the compound, a fusion protein comprising a copy of it, a vector comprising DNA encoding the fusion protein, and a pharmaceutical composition comprising the compound.

Methods for improving the specific binding ability of bispecific binding compositions are described. The bispecific binding compositions are able to target cells by a high affinity targeting domain to a target cell surface marker and a low affinity binding domain that binds specifically to a second cell surface marker, wherein the binding of each domain to its respective cell surface marker increases or decreases, as desired, the biological activity of the respective cell surface markers. The invention further provides bispecific binding agents for use in the methods, as well as uses for the agents.

Sodium nonatitanate compositions, a method using the composition for recovery of 82Sr from irradiated targets, and a method using the composition for generating 82Rb. The sodium nonatitanate materials of the invention are highly selective at separating strontium from solutions derived from the dissolution of irradiated target materials, thus reducing target processing times. The compositions also have a very low affinity for rubidium, making it an ideal material for use as a 82Rb generator. Sodium nonatitanate materials of this type both improve the recovery of 82Sr and provide a safer, more effective 82Rb generator system.

Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agent are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided.

Provided herein are methods of treating obesity and diabetes with labile bile acid sequestrants. An effective amount of a labile bile acid sequestrant may be orally administered to an obese or diabetic individual. A labile bile acid sequestrant provided herein may have a low affinity in the colon or rectum of a human for at least one bile acid or bile acid mimic that stimulates L-cells. A labile bile acid sequestrant may be a non-systemic labile bile acid sequestrant.

The present disclosure relates to bispecific polypeptides comprising a first and a second immunoglobulin single variable domain (ISV), wherein said first ISV binds to a first target on the surface of a cancer cell with a low affinity and, when bound inhibits a function of said first target, and a said second ISV binds to a second target on the surface of said cell with a high affinity and wherein said first target is different from said second target. The present invention further discloses methods for identifying and making the same.

The invention is directed to a cross-screening system and methods of the invention utilizing a combination of an immunoassay (IA) and electrochemiluminescence assay (ECLA) to identify molecules that have binding affinities for a target molecule. The cross-screening system and methods of the invention can detect molecules that have binding affinities for the target molecule below the detection limits of the individual immunoassay or ECLA. The cross-screening system and methods of the invention are useful for generating a pool of candidate analyte molecules enriched in a desired characteristic, such as low binding affinity for a target molecule. Low affinity antibodies identified by the cross-screening system and methods of the invention are useful, for example, in assessing the safety and efficacy of biological therapeutics.

A smoking article capable of delivering a regulated smoke composition to a smoker, includes: a) a combustible filler wrapped in a combustible sheath; and b) at least one affinity chromatographic filter unit designed to preferentially remove specific targeted components from the smoke disposed within the sheath adjacent the combustible filler. The filter unit includes a mass of silica or resin particles having chemically bonded to their surfaces functional groups which exhibit preferential affinity for the targeted components and which reversibly bind the targeted components to elute components having a lower affinity than a previously bound component.

An object of the present invention is to create a novel engineered Protein A ligand having better antibody dissociation properties in the acidic condition compared with known engineered Protein A ligands. The present invention provides a protein having an affinity for an immunoglobulin, including an amino acid sequence obtained by introducing, into an amino acid sequence derived from any of E, D, A, B and C domains of Protein A, at least one amino acid substitution at any one or more of amino acid residues corresponding to positions 31 to 37 of the A, B and C domains (positions 29 to 35 of the E domain, positions 34 to 40 of the D domain), which are conserved in all the domains, the protein having a lower affinity for an Fab region of an immunoglobulin than a protein having the amino acid sequence before introduction of the substitution.

In a glass panel arrangement for automotive sun roof systems having a weather strip frame which is disposed substantially flush with the glass panel, a support frame made of metallic material and attached to a lower surface of the glass panel along a peripheral part of the glass panel is provided with an outer extension for supporting a part of the weather strip frame extending away from the edge of the glass panel from below so as to resist the tendency for the weather strip frame to get detached from the outer periphery of the glass panel. Therefore, the weather strip frame can be made of plastic material which has a relatively low affinity with the glass panel. In particular, if the outer extension is provided with an upwardly directed flange, not only the retaining force of the outer extension is improved but also the bending rigidity of the outer extension is improved.

The present invention provides oligomers that binds RNA that consists of a lower affinity region and a higher affinity region, wherein the monomers in the higher affinity region increases the melting temperature (i.e. affinity) of the oligomer base paired to RNA more than the monomers used in the lower affinity region, wherein said increase in melting temperature is relatively to the alternative use of DNA monomers of the same (base) sequence. The oligomers of the invention are useful for binding to target RNA such as mRNA and non-coding RNA and have the advantage that they will be less prone to off-target binding via the lower affinity region than via the higher affinity region.

Provided is a zinc-plated steel sheet for hot pressing having outstanding surface characteristics, comprising: a steel foundation plate comprising a metal surface diffusion layer of which the Gibbs free energy reduction per mole of oxygen during oxidation is less than that of Cr; an aluminum-rich layer containing at least 30 wt. % of aluminium formed on the surface diffusion layer, and a zinc plating layer formed on the aluminum-rich layer. In this way, a metal having a low affinity for oxygen is coated to an effective thickness prior to annealing and thus the creation of annealing oxides at the surface of the steel sheet is suppressed and a uniform zinc plating layer is formed, and alloying of the zinc plating layer is promoted during press-processing heat treatment. Cracking in the steel foundation plate during hot press molding is prevented.

The invention relates to a making method of an organic-inorganic hybrid separating membrane. Present making methods of organic-inorganic hybrid membranes are characterized in that inorganic particles are directly added into an organic polymer membrane casting liquid, and have the problems of easy agglomeration caking, uneven dispersion and poor membrane making repeatability due to high surface energy of inorganic particles and low affinity with the polymer membrane material. The method comprises the following steps: modifying the surface of the inorganic nanoparticles in order to reduce the surface energy and enhance the compatibility with the polymer membrane material; and mixing the surface modified inorganic nanoparticles with the polymer membrane material, an additive and a solvent to obtain the membrane casting liquid, and making the flat or hollow fiber organic-inorganic hybrid separating membrane through a traditional phase transformation technology. Compared with the prior art, the method significantly inhibits the agglomeration phenomenon of the inorganic nanoparticles, improves the dispersion of the inorganic nanoparticles in the membrane casting liquid, and has better membrane making repeatability. The organic-inorganic hybrid separating membrane made in the invention has good separation characteristic, mechanical strength and anti-pollution performance.

The present invention provides antibodies that bind to CD3 with weak or no detectable binding affinity and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with low affinity and induce human T cell proliferation and hence induce T cell-mediated killing of tumor cells with high efficacy. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3 with weak or no detectable binding affinity in an in vitro assay, and a second antigen-binding molecule that specifically binds human tumor-associated antigen. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing target antigen, such as PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers or other diseases where immunotherapy, i.e. effector cell immunomodulation is warranted.

The present invention provides methods for making novel, rationally designed lowered affinity antibodies. The methods of the present invention make antibodies that have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall (3) dimensional antibody structure. Using the antibodies made using methods of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates.

It is an object of the present invention to provide means for efficiently obtaining peptides that exhibit a high affinity toward a given target. Peptides are designed by the steps of (1) performing an affinity assay using a plurality of peptides having different peptide sequences and a target to obtain affinity data for each of the peptide sequences toward the target; (2) selecting high-affinity peptide sequences and low-affinity peptide sequences; (3) digitizing predetermined property(ies) of amino acids for each location from N-terminal or C-terminal to transform each of the selected peptide sequences into numerical data; (4) performing Fuzzy Neural Network analysis by using the obtained numerical data as input variables to construct a prediction model; (5) extracting from the constructed prediction model one or two or more rules wherein the amino acids and the properties are related to each other on one or more locations on the sequences, said rules representing the characteristics of high-affinity peptide sequence; and (6) designing a peptide according to the extracted rules.